Biomaterial-based delivery of neurotrophic factors to the Parkinsonian brain. (360G-Wellcome-202298_Z_16_Z)
A disease-modifying neuroprotective therapy remains a vital but unmet clinical need in the treatment of Parkinson's disease. One potential neuroprotective agent is the neurotrophic factor, GDNF, but its progress through clinical trials has been hampered due to issues with delivery. One novel delivery system that has the potential to overcome some of the issues associated with current GDNF delivery methods is the use of biomaterials as protein delivery vectors. This, in this project, we aim to determine the safety (biocompatibility and biodegradablity) and preliminary efficacy (kinetics of GDNF release) of GDNF-loaded collagen microspheres in the rat brain. If we can show that this novel therapy is safe in the rat brain, and can provide sustained delivery of GDNF, then this will indicate its potential as a treatment for the human condition.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 2000 |
| Applicant Surname | Egan |
| Approval Committee | Internal Decision Panel for C&S |
| Award Date | 2016-04-01T00:00:00+00:00 |
| Financial Year | 2015/16 |
| Grant Programme: Title | Vacation Scholarships |
| Internal ID | 202298/Z/16/Z |
| Lead Applicant | Miss Hannah Egan |
| Partnership Value | 2000 |
| Planned Dates: End Date | 2016-07-23T00:00:00+00:00 |
| Planned Dates: Start Date | 2016-05-23T00:00:00+00:00 |
| Recipient Org: Country | Ireland |
| Region | Ireland |